

119TH CONGRESS
2D SESSION

H. R. 5160

AN ACT

To reauthorize the Stem Cell Therapeutic and Research Act
of 2005, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Stem Cell Therapeutic
3 and Research Reauthorization Act of 2025”.

4 **SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL**
5 **TRANSPLANTATION PROGRAM.**

6 Section 379B of the Public Health Service Act (42
7 U.S.C. 274m) is amended—

8 (1) by striking “appropriated \$31,009,000” and
9 inserting the following: “appropriated—

10 “(1) \$31,009,000”;

11 (2) in paragraph (1), as so inserted, by striking
12 the period at the end and inserting “; and”; and

13 (3) by adding at the end the following:

14 “(2) \$33,009,000 for each of fiscal years 2027
15 through 2031.”.

16 **SEC. 3. CORD BLOOD INVENTORY.**

17 (a) IN GENERAL.—Section 2(a) of the Stem Cell
18 Therapeutic and Research Act of 2005 (42 U.S.C. 274k
19 note) is amended by striking “at least 150,000 new units
20 of high-quality cord blood” and inserting “a sufficient sup-
21 ply, as determined by the Secretary, of high-quality cord
22 blood units”.

23 (b) APPLICATION.—Section 2(c) of such Act (42
24 U.S.C. 274k note) is amended—

25 (1) in paragraph (2), by striking “in perpetuity
26 or”; and

1 (2) by amending paragraph (5) to read as fol-
2 lows:

3 “(5) if the Secretary determines through an as-
4 sessment, or through petition by the applicant, that
5 a cord blood bank is no longer operational, does not
6 meet the requirements described in subsection
7 (d)(4), or does not meet the requirements of section
8 379(d)(4) of the Public Health Service Act, and as
9 a result may not distribute the high-quality units,
10 the Secretary may transfer the units collected pursu-
11 ant to this section to another qualified cord blood
12 bank or entity approved by the Secretary to ensure
13 continued availability of high-quality cord blood
14 units.”.

15 (c) DURATION OF CONTRACTS.—Section 2(d)(4) of
16 such Act (42 U.S.C. 274k note) is amended to read as
17 follows:

18 “(4) CONSIDERATION OF BEST SCIENCE.—The
19 Secretary shall take into consideration current sci-
20 entific and clinical information in order to maximize
21 the availability of high-quality cord blood units meet-
22 ing applicable clinical and quality standards for
23 transplant when entering into contracts under this
24 section, or when extending a period of funding under
25 such a contract under paragraph (2).”.

1 (d) INVENTORY MANAGEMENT.—Section 2 of such
2 Act (42 U.S.C. 274k note) is amended—

3 (1) by redesignating subsections (e), (f), and
4 (g) and as subsections (f), (g), and (h), respectively;
5 and

6 (2) by inserting after subsection (d) the fol-
7 lowing:

8 “(e) INVENTORY MANAGEMENT.—

9 “(1) IN GENERAL.—The Secretary shall man-
10 age the size and composition of the National Cord
11 Blood Inventory to maximize clinical utility, ensure
12 genetic diversity, and promote the efficient use of re-
13 sources.

14 “(2) CONSIDERATIONS.—In carrying out para-
15 graph (1), the Secretary may—

16 “(A) on the Secretary’s own initiative or
17 upon petition by a qualified cord blood bank,
18 make determinations regarding the continued
19 storage of cord blood units based on the best
20 available scientific and clinical evidence; or

21 “(B) prioritize the collection, retention, or
22 disposition of cord blood units based on sci-
23 entific, clinical, or operational considerations
24 that the Secretary determines to be relevant.”.

1 (e) DEFINITIONS.—Section 2(g) of such Act, as re-
2 designated by subsection (d)(1) of this section, is amend-
3 ed—

4 (1) by redesignating paragraphs (4) and (5) as
5 paragraphs (5) and (6), respectively; and

6 (2) by inserting after paragraph (3) the fol-
7 lowing:

8 “(4) The term ‘high quality cord blood unit’
9 means a cord blood unit that meets current industry
10 standards and any requirements of the Food and
11 Drug Administration.”.

12 (f) AUTHORIZATION OF APPROPRIATIONS.—Section
13 2(h) of such Act, as redesignated by subsection (d)(1) of
14 this section, is amended by striking “fiscal years 2022
15 through 2026” and inserting “fiscal years 2027 through
16 2031”.

Passed the House of Representatives July 20, 2026.

Attest:

Clerk.

119TH CONGRESS
2^D SESSION

H. R. 5160

AN ACT

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.